Relmada Therapeutics, Inc.
Price Action
Technical Summary
EMERGING TRENDRelmada Therapeutics, Inc. shows underlying uptrend characteristics but has temporarily lost support at the 50-day moving average. Relative strength is leading (RS Rating: 93), indicating clear outperformance against the broad market. Earnings growth of 62% provides fundamental context to the price action. Investors should exercise caution due to high volatility (119% annualized), which requires wider risk management.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $6.51 | +2.79% | ABOVE |
| 50 SMA | $6.96 | -3.86% | BELOW |
| 100 SMA | $6.24 | +7.26% | ABOVE |
| 150 SMA | $5.55 | +20.47% | ABOVE |
| 200 SMA | $4.74 | +41.23% | ABOVE |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is RLMD in an uptrend right now?
RLMD has a trend score of 3/4 based on Minervini's Stage Analysis. Currently showing partial alignment - 3 of 4 trend criteria are met.
Is RLMD overbought or oversold?
RLMD's RSI (14) is 45. The stock is in neutral territory, neither overbought nor oversold.
Is RLMD outperforming the market?
RLMD has a Relative Strength (RS) Rating of 93 out of 99. Yes, RLMD is a market leader, outperforming 93% of all stocks over the past 12 months.
Where is RLMD in its 52-week range?
RLMD is trading at $6.69, which is 84% of its 52-week high ($8.00) and 82% above its 52-week low ($0.55).
How volatile is RLMD?
RLMD has a Beta of 1.56 and 52-week volatility of 119%. It's more volatile than the S&P 500 - expect bigger swings.